| 000 | 01322 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250513132840.0 | ||
| 264 | 0 | _c19980205 | |
| 008 | 199802s 0 0 eng d | ||
| 022 | _a0315-162X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHladunewich, M | |
| 245 | 0 | 0 |
_aRaynaud's phenomenon and digital gangrene as a consequence of treatment for Kaposi's sarcoma. _h[electronic resource] |
| 260 |
_bThe Journal of rheumatology _cDec 1997 |
||
| 300 |
_a2371-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadverse effects |
| 650 | 0 | 4 |
_aBleomycin _xadverse effects |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFingers |
| 650 | 0 | 4 |
_aGangrene _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPlethysmography |
| 650 | 0 | 4 |
_aRaynaud Disease _xchemically induced |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSarcoma, Kaposi _xcomplications |
| 650 | 0 | 4 |
_aVinblastine _xadverse effects |
| 700 | 1 | _aSawka, C | |
| 700 | 1 | _aFam, A | |
| 700 | 1 | _aFranssen, E | |
| 773 | 0 |
_tThe Journal of rheumatology _gvol. 24 _gno. 12 _gp. 2371-5 |
|
| 999 |
_c9385220 _d9385220 |
||